Now showing items 1-3 of 3

    • MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. 

      Jaco, I; Annibaldi, A; Lalaoui, N; Wilson, R; Tenev, T; et al. (CELL PRESS, 2017-06-01)
      TNF is an inflammatory cytokine that upon binding to its receptor, TNFR1, can drive cytokine production, cell survival, or cell death. TNFR1 stimulation causes activation of NF-κB, p38α, and its downstream effector kinase ...
    • RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. 

      Smith, HG; Jamal, K; Dayal, JH; Tenev, T; Kyula-Currie, J; et al. (WILEY, 2020-06-08)
      Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ...
    • Targeting RIPK1 ubiquitylation to promote anti-tumour immunity 

      Meier, P; Jamal, K; Meier, P (Institute of Cancer Research (University Of London), 2019-11-30)
      Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ...